0 786

Cited 34 times in

Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author김영진-
dc.contributor.author박준용-
dc.contributor.author송기준-
dc.contributor.author안상훈-
dc.contributor.author한광협-
dc.date.accessioned2017-10-26T08:13:40Z-
dc.date.available2017-10-26T08:13:40Z-
dc.date.issued2016-
dc.identifier.issn1542-3565-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/153170-
dc.description.abstractBACKGROUND & AIMS: We performed a propensity-score matched analysis to investigate whether entecavir, compared with lamivudine, can reduce risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B after adjusting for level of fibrosis. METHODS: We performed a retrospective study of 1079 patients with chronic hepatitis B who received first-line therapy with lamivudine (n = 435) or entecavir (n = 644) from 2006 through 2013. Only patients with available liver stiffness value measured by transient elastography were recruited. Liver cirrhosis was diagnosed by ultrasonography. To adjust for the imbalance of patients treated with lamivudine versus entecavir, we performed propensity-score matching (PSM), at a ratio of 1:1, using 7 factors (age, sex, hepatitis B e antigen, alanine aminotransferase, serum albumin, platelet count, and liver stiffness; PSM1) or 8 factors (variables of PSM1 plus ultrasonography measurements of cirrhosis; PSM2). Patients with virologic breakthrough or resistance mutations received rescue therapy. RESULTS: Over the 7-year period, 91 patients developed HCC and 104 had liver-related events in the entire cohort. In multivariate analyses, level of fibrosis, but not antiviral regimen, was independently associated with risk of HCC (P < .05). The PSM1 group included 342 pairs of patients and the PSM2 group included 338 pairs. Similar proportions of patients given lamivudine versus entecavir developed HCC in each model (10.5% given lamivudine vs 9.9% given entecavir in PSM1 and 11.9% vs 12.6% in PSM2; all P > .05). When PSM was applied to patients with liver stiffness value ≤13 kPa or >13 kPa, patients given lamivudine versus entecavir still had similar cumulative rates of HCC development (all P > .05). CONCLUSIONS: In a PSM analysis, we associated level of fibrosis, rather than antiviral regimen, with risk of HCC, when patients received appropriate rescue therapy in case of virologic breakthrough or resistance mutations.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherW.B. Saunders-
dc.relation.isPartOfCLINICAL GASTROENTEROLOGY AND HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAntiviral Agents/therapeutic use*-
dc.subject.MESHCarcinoma, Hepatocellular/prevention & control*-
dc.subject.MESHElasticity Imaging Techniques-
dc.subject.MESHFemale-
dc.subject.MESHGuanine/analogs & derivatives-
dc.subject.MESHGuanine/therapeutic use-
dc.subject.MESHHepatitis B, Chronic/complications*-
dc.subject.MESHHepatitis B, Chronic/drug therapy*-
dc.subject.MESHHumans-
dc.subject.MESHLamivudine/therapeutic use-
dc.subject.MESHLiver/diagnostic imaging-
dc.subject.MESHLiver/pathology-
dc.subject.MESHLiver Cirrhosis/complications*-
dc.subject.MESHLiver Cirrhosis/drug therapy*-
dc.subject.MESHLiver Neoplasms/prevention & control*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPropensity Score-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTreatment Outcome-
dc.titleAssociation Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B-
dc.typeArticle-
dc.publisher.locationUnited States-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorHye Soo Kim-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorKi Jun Song-
dc.contributor.googleauthorJung Won Park-
dc.contributor.googleauthorYeong Jin Kim-
dc.contributor.googleauthorOidov Baatarkhuu-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorSang Hoon Ahn-
dc.identifier.doi10.1016/j.cgh.2016.05.039-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA00725-
dc.contributor.localIdA01675-
dc.contributor.localIdA02016-
dc.contributor.localIdA02226-
dc.contributor.localIdA04268-
dc.contributor.localIdA00385-
dc.relation.journalcodeJ02981-
dc.identifier.eissn1542-7714-
dc.relation.journalsince2003-
dc.identifier.pmid27305847-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S1542356516303032?via%3Dihub-
dc.subject.keywordEntecavir-
dc.subject.keywordHepatocellular Carcinoma-
dc.subject.keywordLamivudine-
dc.subject.keywordTransient Elastography-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameKim, Beom Kyung-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.alternativeNameKim, Young Jin-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNameSong, Ki Jun-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Beom Kyung-
dc.contributor.affiliatedAuthorKim, Seung Up-
dc.contributor.affiliatedAuthorKim, Young Jin-
dc.contributor.affiliatedAuthorPark, Jun Yong-
dc.contributor.affiliatedAuthorSong, Ki Jun-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.citation.volume14-
dc.citation.number11-
dc.citation.startPage1647-
dc.citation.endPage1656-
dc.identifier.bibliographicCitationCLINICAL GASTROENTEROLOGY AND HEPATOLOGY, Vol.14(11) : 1647-1656, 2016-
dc.date.modified2017-10-24-
dc.identifier.rimsid41165-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.